BreathePeer-Reviewed Publications
Clinical Impact Reach
Clinicians Trained
Protocol Adoption Rate
Where every question
begins with oxygen.
Our investigators formulate hypotheses at the intersection of molecular biology and clinical observation — asking why some patients with IPF progress in months while others plateau for years, and what the mucociliary escalator reveals about early COPD onset.
Grant-Funded Hypothesis Formation
$42M in active NIH, Wellcome Trust, and CIHR grants spanning 18 active studies across ILD, bronchiectasis, and rare airway disorders.
Laser Confocal Microscopy Core
Sub-micron resolution imaging of live bronchial epithelium — capturing cilia beat frequency and mucus viscoelasticity in real time.
Multi-Site Cohort Enrollment
Longitudinal patient registries across Toronto, Amsterdam, and Melbourne with 4,200+ enrolled participants since 2018.
MucoFlow-3 Trial
Phase II — mucociliary clearance in post-COVID bronchiectasis. Enrollment: 312/400 participants.
78% enrolled
Spirometry Benchmarks
Cohort median vs. GOLD reference values
Double-blind RCT
6 active trials
Adaptive Design
Bayesian endpoints
Rigorous design,
reproducible results.
Every protocol is engineered for clinical transferability. Adaptive Bayesian trial designs let us update interim analyses without inflating Type I error — so findings reach treating physicians faster without sacrificing statistical integrity.
CONSORT-compliant reporting for all interventional trials
Pre-registered on ClinicalTrials.gov and ISRCTN before first enrollment
Independent DSMB review at 25%, 50%, and 75% recruitment milestones
Open data-sharing under FAIR principles within 12 months of publication
Cilia-driven mucus transport velocity as an early biomarker of irreversible airway remodelling in fibrotic ILD: a prospective multicentre cohort study
Background: Mucociliary transport velocity (MTV) measured by laser particle-tracking microscopy correlates with FVC decline at 12 months in patients with connective tissue disease–associated ILD (CTD-ILD), independent of baseline HRCT fibrosis score…
Okafor DI, van der Berg M, Krishnamurthy S, et al. Lancet Respiratory Medicine. 2026;14(2):e88–e101.
Data that speaks
at cellular resolution.
From HRCT texture analysis to single-cell RNA sequencing of bronchoalveolar lavage fluid — our analytical pipeline turns raw measurements into actionable clinical signals.
Quantitative lung texture analysis across 12,000+ HRCT scans
Serum Biomarker Panel
KL-6 / MUC1
ILD severity & progression
SP-D
Alveolar epithelial integrity
IL-8 / CXCL8
Neutrophilic airway inflammation
CC-16
Clara cell secretory protein
CYFRA 21-1
Cytokeratin 19 fragment
YKL-40
Chitinase-like glycoprotein
scRNA-seq Atlas
Single-cell transcriptomics of 340,000 BAL cells across 94 patients — identifying aberrant basaloid populations predictive of progressive fibrosis.
ML Prognostic Models
Gradient-boosted ensemble models integrating spirometry, HRCT texture, and serum biomarkers achieve AUC 0.91 for 24-month mortality prediction in IPF.
Global Analysis Network
Federated learning infrastructure connects 14 institutions across North America, Europe, and Oceania — training models on local data without patient transfer.
Findings that change
what happens Monday morning.
Research that never reaches the bedside is research half-finished. Every Breathe study is designed with an implementation pathway — from journal publication to CME module to updated institutional protocol within 18 months of primary results.
ILD Multidisciplinary Discussion Protocol
AJRCCM 2025Standardised MDD framework integrating HRCT, BAL, and biopsy findings — reduces diagnostic discordance by 38%.
Ventilator-Weaning Decision Support Algorithm
Critical Care Medicine 2024Spontaneous breathing trial protocol with integrated diaphragm ultrasound thresholds, reducing reintubation by 22%.
Mucociliary Clearance Enhancement Bundle
ERJ 2025Oscillating PEP + hypertonic saline sequencing protocol for bronchiectasis — 31% reduction in exacerbation frequency.
"The ILD MDD protocol halved our diagnostic uncertainty rate in the first quarter of adoption."
Dr. Priya Venkataraman — Respiratory Lead, St. Vincent's Hospital Melbourne
CME Module Library
Accredited by ATS, ERS, and TSANZ
28
Modules
4.8
Avg rating
14k
Completions
Join the conversation
already in progress.
Access our curated collection of white papers, trial summaries, and imaging atlases — used by clinicians across three continents to refine how they diagnose and treat airway disease.
14 White Papers
ILD, COPD, bronchiectasis
6 Trial Summaries
Phase II & III results
Imaging Atlas
2,400+ annotated HRCT scans
28 CME Modules
ATS/ERS accredited
Access the Research Library
Instant access · No payment required
We respect clinical privacy. No spam, no data resale. Unsubscribe anytime.